Truepoint Inc. grew its holdings in Merck & Company, Inc. (NYSE:MRK) by 0.1% during the second quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 4,221 shares of the company’s stock after purchasing an additional 5 shares during the period. Truepoint Inc.’s holdings in Merck & were worth $268,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds have also added to or reduced their stakes in the business. RB Capital Management LLC increased its stake in Merck & by 0.5% in the second quarter. RB Capital Management LLC now owns 4,587 shares of the company’s stock worth $294,000 after purchasing an additional 23 shares during the period. Baystate Wealth Management LLC increased its stake in Merck & by 0.4% in the second quarter. Baystate Wealth Management LLC now owns 6,470 shares of the company’s stock worth $405,000 after purchasing an additional 27 shares during the period. Bath Savings Trust Co increased its stake in Merck & by 0.5% in the second quarter. Bath Savings Trust Co now owns 5,427 shares of the company’s stock worth $348,000 after purchasing an additional 28 shares during the period. Camelot Portfolios LLC increased its stake in Merck & by 0.4% in the first quarter. Camelot Portfolios LLC now owns 7,771 shares of the company’s stock worth $494,000 after purchasing an additional 33 shares during the period. Finally, Stillwater Investment Management LLC increased its stake in Merck & by 0.8% in the second quarter. Stillwater Investment Management LLC now owns 4,621 shares of the company’s stock worth $296,000 after purchasing an additional 38 shares during the period. Institutional investors and hedge funds own 72.84% of the company’s stock.

In other Merck & news, Director Thomas H. Glocer sold 5,000 shares of the firm’s stock in a transaction dated Wednesday, November 8th. The stock was sold at an average price of $56.20, for a total value of $281,000.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. 0.25% of the stock is currently owned by company insiders.

ILLEGAL ACTIVITY WARNING: “Merck & Company, Inc. (MRK) Holdings Increased by Truepoint Inc.” was reported by Watch List News and is owned by of Watch List News. If you are accessing this report on another publication, it was copied illegally and republished in violation of U.S. & international copyright and trademark law. The original version of this report can be read at https://www.watchlistnews.com/merck-company-inc-mrk-holdings-increased-by-truepoint-inc/1694833.html.

Shares of Merck & Company, Inc. (NYSE:MRK) opened at $55.48 on Friday. The company has a quick ratio of 1.21, a current ratio of 1.43 and a debt-to-equity ratio of 0.57. The firm has a market capitalization of $153,140.61, a PE ratio of 14.45, a price-to-earnings-growth ratio of 2.42 and a beta of 0.78. Merck & Company, Inc. has a twelve month low of $54.41 and a twelve month high of $66.80.

Merck & (NYSE:MRK) last issued its quarterly earnings results on Friday, October 27th. The company reported $1.11 earnings per share for the quarter, topping the consensus estimate of $1.03 by $0.08. The business had revenue of $10.33 billion during the quarter, compared to the consensus estimate of $10.54 billion. Merck & had a return on equity of 27.08% and a net margin of 11.60%. The company’s quarterly revenue was down 2.0% on a year-over-year basis. During the same quarter last year, the company earned $1.07 earnings per share. sell-side analysts forecast that Merck & Company, Inc. will post 3.95 EPS for the current year.

A number of equities analysts have recently issued reports on the company. J P Morgan Chase & Co set a $70.00 price target on Merck & and gave the stock a “buy” rating in a research report on Sunday, October 29th. Berenberg Bank reissued a “hold” rating on shares of Merck & in a research report on Wednesday, November 1st. BMO Capital Markets set a $70.00 price target on Merck & and gave the stock a “buy” rating in a research report on Wednesday, October 18th. Zacks Investment Research downgraded Merck & from a “hold” rating to a “sell” rating in a research report on Wednesday, October 11th. Finally, Credit Suisse Group reissued an “outperform” rating and set a $74.00 price target (down previously from $75.00) on shares of Merck & in a research report on Tuesday, September 5th. Two investment analysts have rated the stock with a sell rating, eleven have issued a hold rating and nine have issued a buy rating to the stock. The company currently has a consensus rating of “Hold” and an average target price of $67.07.

About Merck &

Merck & Co, Inc is a global healthcare company. The Company offers health solutions through its prescription medicines, vaccines, biologic therapies and animal health products. It operates through four segments: Pharmaceutical, Animal Health, Healthcare Services and Alliances. The Company’s Pharmaceutical segment includes human health pharmaceutical and vaccine products marketed either directly by the Company or through joint ventures.

Want to see what other hedge funds are holding MRK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Merck & Company, Inc. (NYSE:MRK).

Institutional Ownership by Quarter for Merck & (NYSE:MRK)

Receive News & Ratings for Merck & Company Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck & Company Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.